The low death rate of BMDCs in response to Lap treatment suggests that the most of the dsDNAs in the post-treatment TME are originated from tumor cells and supports the tumor-specificity of the nanoagonist-stimulated cGAS-STING-mediated immunity. This evidence concerns the gene CGAS and neoplasm.